NACLC 23
Comprehensive and educational content from 2023 IASLC North America Conference on Lung Cancer (NACLC), taking place December 1-3, 2023, in Chicago, IL.
Chemotherapy-induced myelosuppression among patients with extensive-stage SCLC is poorly understood.
The VISION study that evaluated pre/post-tepotinib treatment in advanced/metastatic METex14 skipping NSCLC.
The DeLLphi-301 study that evaluated patients with advanced SCLC.
Results of a study that evaluated the impact of comprehensive versus limited NGS for advanced NSCLC.
A study evaluated second-line treatment patterns and clinical outcomes of IO in NSCLC.
Patients with metastatic NSCLC who receive first-line anti-PD-L1-based IO may achieve durable disease control.
Lurbinectedin monotherapy is currently being studied in Jazz EMERGE 402 study in patients with metastatic SCLC.
Black and/or socioeconomically disadvantaged patients with advanced NSCLC have higher mortality rates.
Results of a lung screening program found a significantly higher lung cancer prevalence in veterans.
A greater understanding of patients with HER2-mutated NSCLC is critical for developing therapies.
Advertisement
Advertisement
